Iovance Biotherapeutics I...

AI Score

0

Unlock

5.89
0.11 (1.90%)
At close: Jan 14, 2025, 3:59 PM
6.11
3.74%
Pre-market Jan 15, 2025, 09:07 AM EST

Iovance Biotherapeutics Statistics

Share Statistics

Iovance Biotherapeutics has 304.78M shares outstanding. The number of shares has increased by 9.12% in one year.

Shares Outstanding 304.78M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.42%
Owned by Institutions (%) n/a
Shares Floating 247.04M
Failed to Deliver (FTD) Shares 10.41K
FTD / Avg. Volume 0.14%

Short Selling Information

The latest short interest is 59.33M, so 19.47% of the outstanding shares have been sold short.

Short Interest 59.33M
Short % of Shares Out 19.47%
Short % of Float 24.01%
Short Ratio (days to cover) 8.82

Valuation Ratios

The PE ratio is -4.31 and the forward PE ratio is -11.82.

PE Ratio -4.31
Forward PE -11.82
PS Ratio 1607.75
Forward PS 2.4
PB Ratio 3.27
P/FCF Ratio -4.98
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Iovance Biotherapeutics Inc. has an Enterprise Value (EV) of 1.87B.

EV / Earnings -4.22
EV / Sales 1574.93
EV / EBITDA -4.38
EV / EBIT -4.07
EV / FCF -4.88

Financial Position

The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.13.

Current Ratio 2.79
Quick Ratio 2.7
Debt / Equity 0.13
Total Debt / Capitalization 11.49
Cash Flow / Debt -4.77
Interest Coverage 0

Financial Efficiency

Return on equity (ROE) is -0.76% and return on capital (ROIC) is -69.19%.

Return on Equity (ROE) -0.76%
Return on Assets (ROA) -0.57%
Return on Capital (ROIC) -69.19%
Revenue Per Employee 2.13K
Profits Per Employee -797.19K
Employee Count 557
Asset Turnover 0
Inventory Turnover 1.04

Taxes

Income Tax -3.48M
Effective Tax Rate 0.01

Stock Price Statistics

The stock price has increased by -29.63% in the last 52 weeks. The beta is 0.59, so Iovance Biotherapeutics 's price volatility has been higher than the market average.

Beta 0.59
52-Week Price Change -29.63%
50-Day Moving Average 8.56
200-Day Moving Average 9.73
Relative Strength Index (RSI) 26.25
Average Volume (20 Days) 7.32M

Income Statement

In the last 12 months, Iovance Biotherapeutics had revenue of 1.19M and earned -444.04M in profits. Earnings per share was -1.89.

Revenue 1.19M
Gross Profit -9.57M
Operating Income -460.56M
Net Income -444.04M
EBITDA -427.43M
EBIT -460.56M
Earnings Per Share (EPS) -1.89
Full Income Statement

Balance Sheet

The company has 114.89M in cash and 75.86M in debt, giving a net cash position of 39.03M.

Cash & Cash Equivalents 114.89M
Total Debt 75.86M
Net Cash 39.03M
Retained Earnings -2.01B
Total Assets 991.12M
Working Capital 380.52M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -361.82M and capital expenditures -22.29M, giving a free cash flow of -384.11M.

Operating Cash Flow -361.82M
Capital Expenditures -22.29M
Free Cash Flow -384.11M
FCF Per Share -1.63
Full Cash Flow Statement

Margins

Gross margin is -804.54%, with operating and profit margins of -38.73K% and -37.35K%.

Gross Margin -804.54%
Operating Margin -38.73K%
Pretax Margin -37.64K%
Profit Margin -37.35K%
EBITDA Margin -35.95K%
EBIT Margin -38.73K%
FCF Margin -32.31K%

Dividends & Yields

IOVA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -32.09%
FCF Yield -21.4%
Dividend Details

Analyst Forecast

The average price target for IOVA is $23, which is 290.5% higher than the current price. The consensus rating is "Buy".

Price Target $23
Price Target Difference 290.5%
Analyst Consensus Buy
Analyst Count 9
Stock Forecasts

Stock Splits

The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.

Last Split Date Sep 26, 2013
Split Type backward
Split Ratio 1:100

Scores

Altman Z-Score 2.3
Piotroski F-Score 4